Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

BMN 701 Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease (INSPIRE Study)

This study has been terminated.
(Sponsor decision)
Information provided by (Responsible Party):
BioMarin Pharmaceutical Identifier:
First received: August 13, 2013
Last updated: March 21, 2017
Last verified: March 2017
Study 701-301 is a single-arm, open-label, switchover study in patients with late-onset Pompe disease who have been receiving treatment with recombinant human acid alpha-glucosidase (rhGAA) for 48 weeks or longer. Ambulatory patients who have mild to moderate respiratory impairment will switch directly to receive BMN 701 20 mg/kg by IV infusion every other week. All participants will receive active drug. No dose of existing therapy will be missed - experimental drug is started immediately.

Condition Intervention Phase
Late-onset Pompe Disease
Drug: BMN 701
Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase 3 Switchover Study of the Efficacy and Safety of BMN 701 (GILT-tagged Recombinant Human GAA) and Long-Term Study for Extended Treatment in rhGAA Exposed Subjects With Late-onset Pompe Disease

Resource links provided by NLM:

Further study details as provided by BioMarin Pharmaceutical:

Primary Outcome Measures:
  • percent predicted MIP (Maximum Inspiratory Pressure) measured at the mouth by the Mueller maneuver [ Time Frame: 24 weeks ]

Secondary Outcome Measures:
  • percent predicted MEP (Maximum Expiratory Pressure) and FVC (Forced Vital Capacity) Upright [ Time Frame: 24 weeks ]
  • 6 Minute Walk Test [ Time Frame: 24 weeks ]

Enrollment: 24
Study Start Date: March 2014
Study Completion Date: March 1, 2017
Primary Completion Date: March 1, 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BMN 701
BMN 701 IV Infusion 20mg/kg every 2 weeks for 24 weeks followed by an optional extension of 240 weeks (total duration of therapy 264 weeks)
Drug: BMN 701


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Willing and able to provide written informed consent, after the nature of the study has been explained, and prior to any study-related procedures.
  • Diagnosed with late-onset Pompe disease based on 2 currently or previously documented GAA gene mutations, and endogenous GAA activity <75% of the lower limit of the normal adult range reported by the testing laboratory, as assessed by dried blood spot or whole blood assay.
  • Has received prior treatment with commercial rhGAA as defined by ALL of the following:

    1. has received treatment with commercial rhGAA for ≥ 48 weeks (but no more than 20% of the study population can have received treatment for ≥ 6 years).
    2. has received > 80% of all scheduled treatments in the prior 48 weeks and ≥ 4 out of the prior 6 scheduled treatments.
    3. has received and completed the last two infusions without a drug-related adverse event resulting in dose interruption.
    4. has received last treatment of commercial rhGAA ≥ 10 and ≤ 31 days prior to anticipated initiation of treatment with BMN 701.
  • ≥ 18 years of age at the time of enrollment in the study.
  • Sexually active subjects must be willing to use two known effective methods of contraception while participating in the study and for at least 4 months following the last dose of BMN 701.
  • Females of childbearing potential must have a negative pregnancy test at Screening and Baseline visits and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been in menopause at least 2 years, or had tubal ligation at least 1 year prior to Screening, or who have had total hysterectomy.
  • Has ≥ 30% predicted upright FVC and < 80% predicted upright FVC.
  • Has ≤60% predicted MIP.
  • Is able to ambulate ≥75 meters and ≤500 meters on the 6MWT conducted during the Screening visit (use of assistive devices such as walker, cane, or crutches, is permitted with consistent use throughout the study).
  • Is willing and able to comply with all study procedures.

Exclusion Criteria:

  • Use of any investigational product or investigational medical device within 4 weeks prior to Screening, or requirement for any investigational agent other than BMN 701 prior to completion of at least the first 24 weeks of all scheduled study assessments.
  • Received any investigational medication for Pompe disease within the prior 12 months.
  • Has a diagnosis of diabetes and/or is currently being treated with or anticipated to require treatment with hypoglycemic agents during the course of the study.
  • Has been treated with any immunosuppressive medication other than glucocorticosteroids within the prior 12 months.
  • Requires noninvasive ventilatory support while awake and in the upright position.
  • Has previously been enrolled to this study.
  • Breastfeeding at Screening or planning to become pregnant (self or partner) at any time during the study.
  • Concurrent disease, medical condition, or extenuating circumstance that, in the opinion of the Investigator, might compromise subject safety, study treatment compliance and completion of the study, or the integrity of the data collected for the study.
  • Has known hypersensitivity to BMN 701 or its excipients.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01924845

  Show 22 Study Locations
Sponsors and Collaborators
BioMarin Pharmaceutical
Study Director: Liron Walsh, MD BioMarin Pharmaceutical
  More Information

Responsible Party: BioMarin Pharmaceutical Identifier: NCT01924845     History of Changes
Other Study ID Numbers: 701-301
2013-001768-48 ( EudraCT Number )
Study First Received: August 13, 2013
Last Updated: March 21, 2017

Additional relevant MeSH terms:
Glycogen Storage Disease Type II
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Glycogen Storage Disease
Carbohydrate Metabolism, Inborn Errors
Lysosomal Storage Diseases
Metabolic Diseases processed this record on April 28, 2017